Tenax Therapeutics to Participate in the Guggenheim Emerging Outlook Biotech Summit 2026

Tenax Therapeutics (Nasdaq: TENX) will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 in New York.

Rhea-AI Summary

Tenax Therapeutics (Nasdaq: TENX) will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 in New York.

When: February 11, 2026 at 12:30 p.m. ET. Participants: Chris Giordano, President & CEO, and Douglas Randall, Chief Business Officer. A live and archived webcast will be available on the company's investor relations webpage.

Argus Feb 4 session

+1.39% close to close Open Argus

Details

News Market Reaction – TENX

On Feb 4, the day this news came out, TENX closed 1.39% above the previous close.

Data tracked by StockTitan Argus for the Feb 4 session.

Market Context

This announcement highlights Tenax’s continued investor outreach via a fireside chat at the Guggenhe...

Analysis

This announcement highlights Tenax’s continued investor outreach via a fireside chat at the Guggenheim Emerging Outlook Biotech Summit on Feb 11, 2026. It fits a recent pattern of conference participation alongside key clinical milestones, including the LEVEL Phase 3 update on Dec 17, 2025. Investors may focus on how management frames trial timelines, the broader TNX-103 program, and existing cash runway through 2027, while monitoring upcoming data and additional regulatory or clinical disclosures.

Key Figures

Share price: $12.95 52-week high: $18.38 52-week low: $4.63 +5 more

Share price

$12.95

Pre-news current price

52-week high

$18.38

52-week range upper bound

52-week low

$4.63

52-week range lower bound

Market cap

$80,854,296

Equity value prior to news

Volume today

141,170 shares

Trading volume on news day

20-day avg volume

341,467 shares

Liquidity benchmark

200-day MA

$7.75

Long-term trend level

Conference time

12:30 p.m. ET

Guggenheim Biotech Summit session on Feb 11, 2026

Historical Context

5 past events · Latest: Dec 17

5 events

1. Dec 17

   Phase 3 design update

   24h Move

   +5.7%

   LEVEL Phase 3 BSSR confirmed >90% power and launch of LEVEL-2 trial.

2. Nov 25

   Investor conferences

   24h Move

   +4.4%

   Announcement of two early-December healthcare conference fireside chats.

3. Nov 12

   Earnings and update

   24h Move

   -0.7%

   Q3 2025 results, LEVEL timelines, patent progress, and cash runway to 2027.

4. Nov 06

   KOL call announcement

   24h Move

   -2.4%

   Planned virtual KOL event to discuss TNX-103 and Phase 3 program.

5. Nov 03

   Guggenheim conference

   24h Move

   -2.3%

   Participation in Guggenheim healthcare conference via fireside chat in Boston.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

phase 3, cardiopulmonary, webcast

3 terms

phase 3 medical

"a Phase 3, development-stage pharmaceutical company using clinical insights"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

cardiopulmonary medical

"develop novel cardiopulmonary therapies, announced today that the Company"

Relating to the combined function of the heart and lungs—how the heart pumps blood and the lungs oxygenate that blood and remove waste gases. Investors watch cardiopulmonary issues because treatments, devices, or clinical results in this area can affect demand, regulatory reviews, hospital spending and patient outcomes; think of the heart and lungs as a vehicle’s engine and fuel system—if either falters, the market for repairs and improvements can change quickly.

webcast technical

"The live and archived webcast of the presentation will be accessible"

A webcast is a live or recorded online event where people watch or listen to presentations, announcements, or performances through the internet. It’s like a TV broadcast but over the internet, allowing viewers from anywhere to tune in in real time or later. Webcasts are important because they let companies share information quickly and widely with audiences around the world.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CHAPEL HILL, N.C., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, announced today that the Company will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026, which is taking place from February 11-12, 2026, in New York, NY.

Details of presentation:
Format: Fireside chat
Participants: Chris Giordano, President & Chief Executive Officer; Douglas Randall, Chief Business Officer
Date and Time: February 11, 2026, at 12:30 p.m. ET

The live and archived webcast of the presentation will be accessible from the Company’s investor relations webpage.

About Tenax Therapeutics

Tenax Therapeutics, Inc. is a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies. The Company owns global rights to develop and commercialize levosimendan, which it is developing for the treatment of PH-HFpEF, the most prevalent form of pulmonary hypertension globally, for which no product has been approved to date. For more information, visit www.tenaxthera.com. Tenax Therapeutics’ common stock is listed on The Nasdaq Stock Market LLC under the symbol “TENX”.

Contact:

Investor and Media:

Argot Partners

tenax@argotpartners.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is Tenax Therapeutics (TENX) presenting at the Guggenheim Emerging Outlook Biotech Summit 2026?

Tenax is presenting on February 11, 2026 at 12:30 p.m. ET. According to the company, the presentation is a fireside chat featuring senior executives and is scheduled during the February 11-12, 2026 summit in New York.

Who will represent Tenax Therapeutics (TENX) in the fireside chat on February 11, 2026?

Chris Giordano and Douglas Randall will represent Tenax in the fireside chat. According to the company, Chris Giordano is President & CEO and Douglas Randall is Chief Business Officer, participating in the February 11 presentation at 12:30 p.m. ET.

How can investors watch the Tenax (TENX) presentation at the Guggenheim biotech summit?

Investors can view a live and archived webcast on Tenax's investor relations webpage. According to the company, the webcast will be accessible both live during the February 11 presentation and archived afterward for later viewing.

What format will Tenax Therapeutics (TENX) use for its Guggenheim summit presentation?

Tenax will present in a fireside chat format with company executives. According to the company, the format is an executive discussion scheduled for February 11, 2026 at 12:30 p.m. ET during the Guggenheim Emerging Outlook Biotech Summit.

Will Tenax (TENX) provide a replay of its Guggenheim Emerging Outlook presentation?

Yes, a replay will be available as an archived webcast on the company's investor relations webpage. According to the company, both the live presentation and an archived version will be accessible after the February 11 session.